These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 37467796)

  • 21. Major Depression Comorbid with Medical Conditions: Analysis of Quality of Life, Functioning, and Depressive Symptom Severity.
    IsHak WW; Steiner AJ; Klimowicz A; Kauzor K; Dang J; Vanle B; Elzahaby C; Reid M; Sumner L; Danovitch I
    Psychopharmacol Bull; 2018 Jan; 48(1):8-25. PubMed ID: 29382957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: a report of OPERATION study.
    Wu Z; Chen J; Yuan C; Hong W; Peng D; Zhang C; Cao L; Fang Y
    J Affect Disord; 2013 Sep; 150(3):834-9. PubMed ID: 23570952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Remission of depression in patients with schizophrenia and comorbid major depressive disorder: results from the FACE-SZ cohort.
    Fond G; Boyer L; Berna F; Godin O; Bulzacka E; Andrianarisoa M; Brunel L; Aouizerate B; Capdevielle D; Chereau I; Coulon N; D'Amato T; Dubertret C; Dubreucq J; Faget C; Leignier S; Lançon C; Mallet J; Misdrahi D; Passerieux C; Rey R; Schandrin A; Urbach M; Vidailhet P; Leboyer M; Schürhoff F; Llorca PM;
    Br J Psychiatry; 2018 Aug; 213(2):464-470. PubMed ID: 29871707
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.
    Rush AJ; Fava M; Wisniewski SR; Lavori PW; Trivedi MH; Sackeim HA; Thase ME; Nierenberg AA; Quitkin FM; Kashner TM; Kupfer DJ; Rosenbaum JF; Alpert J; Stewart JW; McGrath PJ; Biggs MM; Shores-Wilson K; Lebowitz BD; Ritz L; Niederehe G;
    Control Clin Trials; 2004 Feb; 25(1):119-42. PubMed ID: 15061154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comorbid alcohol use disorder in psychiatric MDD patients: A five-year prospective study.
    Holma M; Holma I; Isometsä E
    J Affect Disord; 2020 Apr; 267():283-288. PubMed ID: 32217228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Family history of depression and therapeutic outcome: findings from STAR*D.
    Husain MM; Rush AJ; Wisniewski SR; McClintock SM; Fava M; Nierenberg AA; Davis L; Balasubramani GK; Young E; Albala AA; Trivedi MH
    J Clin Psychiatry; 2009 Feb; 70(2):185-95. PubMed ID: 19192454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
    Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
    Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial.
    Mohamed S; Johnson GR; Chen P; Hicks PB; Davis LL; Yoon J; Gleason TC; Vertrees JE; Weingart K; Tal I; Scrymgeour A; Lawrence DD; Planeta B; Thase ME; Huang GD; Zisook S; ; Rao SD; Pilkinton PD; Wilcox JA; Iranmanesh A; Sapra M; Jurjus G; Michalets JP; Aslam M; Beresford T; Anderson KD; Fernando R; Ramaswamy S; Kasckow J; Westermeyer J; Yoon G; D'Souza DC; Larson G; Anderson WG; Klatt M; Fareed A; Thompson SI; Carrera CJ; Williams SS; Juergens TM; Albers LJ; Nasdahl CS; Villarreal G; Winston JL; Nogues CA; Connolly KR; Tapp A; Jones KA; Khatkhate G; Marri S; Suppes T; LaMotte J; Hurley R; Mayeda AR; Niculescu AB; Fischer BA; Loreck DJ; Rosenlicht N; Lieske S; Finkel MS; Little JT
    JAMA; 2017 Jul; 318(2):132-145. PubMed ID: 28697253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Developing thai economic model to study cost-effectiveness of switching to bupropion compared to combination with bupropion after the failure of an SSRI for major depressive disorder.
    Leelahanaj T
    J Med Assoc Thai; 2010 Nov; 93 Suppl 6():S35-42. PubMed ID: 21284135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of vortioxetine in subjects with major depressive and alcohol use disorders: a 6-month retrospective analysis.
    Di Nicola M; Pepe M; Panaccione I; Moccia L; Dattoli L; Molinaro M; Sani G; Janiri L; McIntyre RS
    CNS Spectr; 2022 Feb; 27(1):73-81. PubMed ID: 32772956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity.
    Jha MK; Minhajuddin A; South C; Rush AJ; Trivedi MH
    Am J Psychiatry; 2019 May; 176(5):358-366. PubMed ID: 30922100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early adversity in chronic depression: clinical correlates and response to pharmacotherapy.
    Klein DN; Arnow BA; Barkin JL; Dowling F; Kocsis JH; Leon AC; Manber R; Rothbaum BO; Trivedi MH; Wisniewski SR
    Depress Anxiety; 2009; 26(8):701-10. PubMed ID: 19434623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    Trivedi MH; Rush AJ; Wisniewski SR; Nierenberg AA; Warden D; Ritz L; Norquist G; Howland RH; Lebowitz B; McGrath PJ; Shores-Wilson K; Biggs MM; Balasubramani GK; Fava M;
    Am J Psychiatry; 2006 Jan; 163(1):28-40. PubMed ID: 16390886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors and Moderators of Remission With Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression: An Analysis of the IRL-GRey Randomized Clinical Trial.
    Kaneriya SH; Robbins-Welty GA; Smagula SF; Karp JF; Butters MA; Lenze EJ; Mulsant BH; Blumberger D; Anderson SJ; Dew MA; Lotrich F; Aizenstein HJ; Diniz BS; Reynolds CF
    JAMA Psychiatry; 2016 Apr; 73(4):329-36. PubMed ID: 26963689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.
    Rush AJ; Trivedi MH; Wisniewski SR; Stewart JW; Nierenberg AA; Thase ME; Ritz L; Biggs MM; Warden D; Luther JF; Shores-Wilson K; Niederehe G; Fava M;
    N Engl J Med; 2006 Mar; 354(12):1231-42. PubMed ID: 16554525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Do baseline sub-threshold hypomanic symptoms affect acute-phase antidepressant outcome in outpatients with major depressive disorder? Preliminary findings from the randomized CO-MED trial.
    Jha MK; Malchow AL; Grannemann BD; Rush AJ; Trivedi MH
    Neuropsychopharmacology; 2018 Oct; 43(11):2197-2203. PubMed ID: 30135556
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of change in suicidal ideation across treatment phases of major depressive disorder: analysis of the STAR*D data.
    Weissman CR; Hadas I; Yu D; Jones B; Kong D; Mulsant BH; Blumberger DM; Daskalakis ZJ
    Neuropsychopharmacology; 2021 Jun; 46(7):1293-1299. PubMed ID: 33479508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial.
    Jha MK; Wakhlu S; Dronamraju N; Minhajuddin A; Greer TL; Trivedi MH
    J Affect Disord; 2018 Jul; 234():34-37. PubMed ID: 29522941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comorbidity between major depression and alcohol use disorder from adolescence to adulthood.
    Brière FN; Rohde P; Seeley JR; Klein D; Lewinsohn PM
    Compr Psychiatry; 2014 Apr; 55(3):526-33. PubMed ID: 24246605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mirtazapine in comorbid major depression and an alcohol use disorder: A double-blind placebo-controlled pilot trial.
    Cornelius JR; Chung T; Douaihy AB; Kirisci L; Glance J; Kmiec J; FitzGerald D; Wesesky MA; Salloum I
    Psychiatry Res; 2016 Aug; 242():326-330. PubMed ID: 27327217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.